ZMA001 for Healthy Adults

Study of Intravenous ZMA001 in Healthy Subjects

Recruiting Phase 1 Interventional Study
Pulmonary Arterial Hypertension PAH
Healthy Volunteers Welcome You do not need to have the condition being studied to take part.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 60
Sex
Any
Trial phase
Phase 1
Study type
Interventional
Purpose
Basic Science
Participants needed
96 (estimated)
Sponsor
National Heart, Lung, and Blood Institute (NHLBI) · NIH
Who this trial is looking for

This trial is looking for healthy adults aged 18 to 60 years. Participants will receive a single dose of a study drug called ZMA001 or a placebo during a hospital stay lasting up to 48 hours.

Are You a Good Fit for This Trial?

You may be able to join if

  • I am a healthy adult between 18 and 60 years old.
  • I am willing to follow all study procedures.
  • I am in good general health.
  • I can sign a written consent document.
  • I agree to use contraception if I am a female capable of becoming pregnant.
  • I will adhere to lifestyle considerations during the study.
  • I am not planning to donate sperm if I am male.

You may not be able to join if

  • I am pregnant or breastfeeding.
  • I have a history of HIV infection.
  • I have severe allergies to medications.
  • I have used tobacco products in the past 3 months.
  • I have used illicit drugs in the past 6 months.
  • I have a significant medical illness that is not controlled.
  • I have a body mass index (BMI) below 17 or above 32.
  • I have received another monoclonal antibody in the past 30 days.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.

Check Your Eligibility
About This Trial
Background: A number of diseases can cause a type of lung injury called pulmonary arterial hypertension (PAH). Most people who develop PAH do not survive more than a few years. A new study drug (ZMA001) may help. ZMA001 is a monoclonal antibody. This type of drug consists of proteins, made in a facility, that are very similar to proteins in a human body. But before giving ZMA001 to people sick wi…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
* INCLUSION CRITERIA: In order to be eligible to participate in this study, an individual must meet all of the following criteria: 1. Stated willingness to comply with all study procedures and availability for the duration of the study 2. Male\* or female, aged 18 to 60 years, inclusive 3. In good…
Contacts

Sandra Cooper Bennett, R.N.

(240) 328-0465

sandra.cooper@nih.gov

CONTACT

Jason M Elinoff, M.D.

(301) 402-4846

elinoffj@mail.nih.gov

CONTACT